Prodromal α-Synucleinopathies

Lana M. Chahine, MD, FAAN Movement Disorders p. 1268-1280 October 2022, Vol.28, No.5 doi: 10.1212/CON.0000000000001153
REVIEW ARTICLES
BROWSE ARTICLES
Article as PDF
-- Select an option --

PURPOSE OF REVIEW This article describes prodromal α-synucleinopathies.

RECENT FINDINGS The pathology underlying α-synucleinopathies, which include Parkinson disease, multiple system atrophy, and dementia with Lewy bodies, begins years before the presence of the full syndrome that is the basis for the clinical diagnosis of each of these disorders. This “prodromal” phase may manifest with various signs or symptoms. In addition to individuals in the prodromal phase, some individuals are asymptomatic but are at risk for α-synucleinopathies owing to genetic predisposition or other risk factors.

SUMMARY Clinicians are increasingly seeing patients in the clinical setting who are prodromal or at risk for α-synucleinopathies, and this article reviews the approach to these patient populations, which includes identifying clinical features, assessment, and counseling.

Address correspondence to Dr Lana M. Chahine, Department of Neurology, University of Pittsburgh, 3471 Fifth Ave, Pittsburgh, PA, 15213, [email protected]om.

RELATIONSHIP DISCLOSURE: Dr Chahine has received personal compensation in the range of $500 to $4999 for serving as a consultant for Gray Matters Technology Services and has received publishing royalties from a publication relating to health care. The institution of Dr Chahine has received research support from the Biogen/Parkinson Study Group, The Michael J. Fox Foundation, and University of Pittsburgh Medical Center.

UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Dr Chahine reports no disclosure.

© 2022 American Academy of Neurology.